REFERENCES 1. Joseph LN, Babikian VL, Allen NC, Winter MR. Risk factor modification in stroke prevention the experience of a stroke clinic. Stroke. 1999;30:16–20. [PubMed]2. Lunardi C, Bason C, Corrocher R, Puccetti A. Induction of endothelial cell damage by hCMV molecular mimicry. TRENDS Immunol. 2005;26:19–24. [PubMed]3. Abbas M, Bignamini V, Corea F. Effects of chronic microbial infection on atherosclerosis. Atherosclerosis. 2006;187:439–40. [PubMed]4. Abbas M, Sessa M, Corea F. Asymptomatic carotid lesions: traditional vs emerging risk factors. Arch Med Res. 2006;37:687–8. [PubMed]5. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311:711–714. [PubMed]6. Martin-de-Argila C, Boixeda D, Canton R, Gisbert JP, Fuertes A. High seroprevalence of Helicobacter pylori infection in coronary heart disease. Lancet. 1995;346:310. [PubMed]7. Phull PS, Gower JD, Price AB, Green CJ, Jacyna MR. Alpha-tocopherol antioxidant levels in chronic gastritis correlation with mucosal neutrophil infiltration. Gut. 1993;34(suppl 1):T133. 8. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255–259. [PubMed]9. Elizalde JI, Gomez J, Panes J, et al. Platelet activation In mice and human Helicobacter pylori infection. J Clin Invest. 1997;100(5):996–1005. [PubMed]10. Kutluana U, Simsek I, Akarsu M, Kupelioglu A, Karasu S, Altekin E. Is there a possible relation between atrophic gastritis and premature atherosclerosis? Helicobacter. 2005;10(6):623–9. [PubMed]11. Ward ME. The immunobiology and immunopathology of chlamydial infections. APMIS. 1995;103:769–796. [PubMed]12. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease a prospective study in middle-aged to elderly men with treated hypertension. Stroke. 1999;30:299–305. [PubMed]13. Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis.Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med. 1993;95:499–504. [PubMed]14. Linnanmäki E, Leinonen M, Mattila K, Neiminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993;87:1130–1134. [PubMed]15. Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke. 1996;27:2207–2210. [PubMed]16. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96:2144–2148. [PubMed]17. Juvonen J, Juvonen T, Laurila A, et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aneurysms. J Vasc Surg. 1997;25:499–505. [PubMed]18. Cook PJ, Honeybourne D, Lip GYH, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia the West Birmingham Stroke Project. Stroke. 1998;29:404–410. [PubMed]19. Abbas MA, Corea F. Surrogate sonographic markers of atherosclerosis. Stroke. 2006;37:1644. [PubMed]20. Yamashita K, Ouch K, Shirai M, Gondo T, Nakazawa T, Ito H. Distribution of Chlamydia pneumoniae infection in the atherosclerotic artery. Stroke. 1998;29:773–778. [PubMed]21. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein an inflammatory marker and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1998;32:35–41. [PubMed]22. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression a potential link to accelerated arteriosclerosis. Circulation. 1999;100:1369–73. [PubMed]23. Kalayoglu MV, Indrawati Morrison RP, Morrison SG, Yuan Y, Byrne GI. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis. 2000;181(suppl 3):S483–S489. [PubMed]24. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge heat shock protein (HSP) 60 activates the innate immune response CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol. 2000;164:13–17. [PubMed]25. Maass M, Gieffers J. Cardiovascular disease risk from prior Chlamydia pneumoniae infection can be related to certain antigens recognized in the immunoblot profile. J Infect. 1997;35:171–176. [PubMed]26. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections immunity and atherosclerosis associations of antibodies to Chlamydia pneumoniae Helicobacter pylori and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000;102:833–839. [PubMed]27. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections role of endothelial dysfunction. Circulation. 2002;106:184–190. [PubMed]28. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans? Clin Microbiol Infect. 2002;8(10):654–61. [PubMed]29. Tutuncu NB, Guvener N, Tutuncu T, et al. Chlamydia pneumonia seropositivity correlates with serum fibrinogen and lipoprotein a levels any role in atherosclerosis? Endocr J. 2001;48:269–274. [PubMed]30. Fryer RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med. 1997;45:168–174. 31. Valtonen VV. Infection as a risk factor for infarction and atherosclerosis. Ann Med. 1991;23:539–543. [PubMed]32. Laurila AL, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Chlamydia pneumoniae antibodies associated with altered serum lipid profile. Int J Circumpolar Health. 1998;57(suppl 1):329–332. [PubMed]33. Murray LJ, O'Reilly DP, Ong GM, O'Neill C, Evans AE, Bamford KB. Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart. 1999;81:239–244. [PubMed]34. Chou S. Newer methods for diagnosis of cytomegalovirus. Rev Infect Dis. 1990;12(Suppl 7):S727–36. [PubMed]35. Koeppen AH, Lansing LS, Peng SK, Smith RS. Central nervous system vasculitis in cytomegalovirus infection. J Neurol Sci. 1981;51:395–410. [PubMed]36. Booss J, Dann PR, Winkler SR, Griffith BP, Kim JH. Mechanisms of injury to the central nervous system following experimental cytomegalovirus infection. Am J Otolaryngol. 1990;11:313–7. [PubMed]37. Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation. 2000;102:1917–1923. [PubMed]38. Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000;85:140–146. [PubMed]39. Blankenberg S, Rupprecht HJ, Bickel C, et al. Cytomegalovirus infection with interleukin- 6 response predicts cardiac mortality in patients with coronary artery disease. Circulation. 2001;103:2915–2921. [PubMed]40. Horvath R. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol. 2000;16:17–24. [PubMed]41. Blum A, Peleg A, Weinberg M. Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis. Clin Exp Med. 2003;3(3):157–160. [PubMed]42. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation. 2003;76:1470–1474. [PubMed]43. Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis. 1998;177:209–212. [PubMed]44. Sorlie PD, Baer JT, Du Laney TV, et al. Nuclear factor-kappaB activation in endothelium by Chlamydia pneumoniae without active infection. J Infect Dis. 2003;188(8):1094–7. [PubMed]45. Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus herpes simplex virus 1 and coronary heart disease the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2000;160:2027–32. [PubMed]46. Sambiase NV, Higuchi ML, Nuovo G, et al. CMV and transplant-related coronary atherosclerosis an immunohistochemical in situ hybridization, and polymerase chain reaction in situ study. Mod Pathol. 2000;13:173–9. [PubMed]47. Grahame-Clarke C, Chan NN, Andrew D, et al. Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation. 2003;108:678–83. [PubMed]48. Rott D, Zhu J, Zhou YF, Burnett MS, Zalles-Ganley A, Epstein SE. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis. 2003;170:223–8. [PubMed]49. Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions a 5-year follow-up study. Stroke. 2006;37:482–6. [PubMed]50. Guech-Ongey M, Brenner H, Twardella D, Hahmann H, Rothenbacher D. Role of cytomegalovirus sero-status in the development of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes. Int J Cardiol. 2006;111:98–103. [PubMed]51. Neau D, Bonnet F, Viallard JF, Longy-Boursier M, Le Bras M. Thrombotic thrombocytopenic purpura and cytomegalovirus infection in an immunocompetent adult. Clin Infect Dis. 1997;25:1495–6. [PubMed]52. Abgueguen P, Delbos V, Chennebault JM, Payan C, Pichard E. Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients report of 2 cases and literature review. Clin Infect Dis. 2003;36:e134–9. [PubMed]53. Kazory A, Ducloux D, Coaquette A, Manzoni P, Chalopin JM. Cytomegalovirus-associated venous thromboembolism in renal transplant recipients a report of 7 cases. Transplantation. 2004;7:597–9. [PubMed]54. de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis inflammation and infection. J Pathol. 2000;190:237–43. [PubMed]55. Streblow DN, Orloff SL, Nelson JA. Do pathogens accelerate atherosclerosis? J Nutr. 2001;131:2798S–2804S. [PubMed]56. Armitage GC. Periodontal infections and cardiovascular disease--how strong is the association? Oral Dis. 2000;6:335–50. [PubMed]57. Ricevuti G, Gritti D, Gasparetto C, Wiedermann CJ. Immune activation as effect modifier of atherogenesis in chronic infection. Int Rev Immunol. 2002;21:27–31. [PubMed]58. Meurman JH, Sanz M, Janket SJ. Oral health atherosclerosis and cardiovascular disease. Crit Rev Oral Biol Med. 2004;15:403–413. [PubMed]59. Corea F, Kwan J, Abbas MA. Predisposition to carotid atherosclerosis in ICARAS Dental Substudy. Stroke. 2006;38:12. [PubMed]60. Naito M, Sakai E, Shi Y, et al. Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase. Mol Microbiol. 2006;59:152–67. [PubMed]61. Mattila KJ, Pussinen PJ, Paju S. Dental infections and cardiovascular diseases a review. J Periodontol. 2005;76(Suppl 11):2085–8. [PubMed]62. Beck JD, Eke P, Lin D, et al. Associations between IgG antibody to oral organisms and carotid intima-medial thickness in community-dwelling adults. Atherosclerosis. 2005;183:342–348. [PubMed]63. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection the Azithromycin in Coronary Artery Disease Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99:1540–1547. [PubMed]64. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes the final report of the ROXIS Study. Eur Heart J. 1999;20:121–127. [PubMed]65. Tiran A, Gruber HJ, Graier WF, Wagner AH, Van Leeuwen EB, Tiran B. Aspirin inhibits Chlamydia pneumoniae-induced nuclear factor-kappa B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:1075–80. [PubMed]66. Lecomte F, Benhamou D. [New macrolides]. Rev Med Interne. 1998;19:255–61. [PubMed]67. Uriarte SM, Molestina RE, Miller RD, et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis. 2002;185:1631–6. [PubMed]68. Gurfinkel E. Link between intracellular pathogens and cardiovascular diseases. Clin Microbiol Infect. 1998;4(Suppl 4):S33–S36. [PubMed]69. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. Antimicrob Agents Chemother. 2002;46:2321–6. [PubMed]70. Grau AJ, Marquardt L, Lichy C. The effect of infections and vaccinations on stroke risk. Expert Rev Neurother. 2006;6:175–83. [PubMed]71. Pesonen E, Andsberg E, Ohlin H, et al. Dual role of infections as risk factors for coronary heart disease. Atherosclerosis. 2007;192:370–5. [PubMed]72. Thorpe C, Edwards L, Snelgrove R, et al. Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine. 2007;25(12):2252–60. [PubMed] |